RP collaboration funding announced
The National Neurovision Research Institute (NNRI) in the US and Adeona Pharmaceuticals Inc. have announced a collaboration to investigate the oral drug flupirtine in the treatment of retinitis pigmentosa (RP).
The National Neurovision Research Institute (NNRI) in the US and Adeona Pharmaceuticals Inc. have announced a collaboration to investigate the oral drug flupirtine in the treatment of retinitis pigmentosa (RP).
NNRI will fund preclinical trials of flupirtine, which has been administered to approximately 27 patients across Europe for five years to treat RP, in several animal models at the Bascom Palmer Eye Institute, Miami, Florida, US.
If the preclinical trial outcomes are positive, Adeona and NNRI will potentially move on to clinical testing.
